Journal of Advances in Medical and Pharmaceutical Sciences

Stage IV non-small cell lung cancer (NSCLC) has long been treated as a domain for systemic therapy and palliation alone, with surgery reserved for managing complications rather than for controlling disease. That position has shifted markedly over the past decade. It is now recognised that a meaningful subset of patients present with, or evolve towards, a limited burden of metastatic disease — the so-called oligometastatic state — and this has prompted a rethink of curative-intent local therapy, including pulmonary resection, as part of multimodality management. Randomised evidence showing a survival benefit from local consolidative therapy, combined with the steady improvement of targeted agents and immune checkpoint inhibitors, has created conditions in which carefully selected patients with synchronous or metachronous oligometastatic NSCLC can achieve prolonged progression-free and overall survival after resection of the primary tumour and, in some cases, of metastatic deposits as well. This review traces how the oligometastatic concept developed, weighs the randomised and observational evidence behind surgical intervention, and works through site-specific considerations affecting the brain, adrenal gland, contralateral lung and pleura. It also looks at how surgery is being integrated with oncogene-targeted agents and immunotherapy, at the practical business of multidisciplinary patient selection, and at the emerging role of molecular and circulating biomarkers in refining who should be offered surgery. The evidence remains largely retrospective and inconsistent in how it defines oligometastasis, yet a fairly consistent signal points to durable benefit in well-selected patients, and recent consensus guidelines have begun to give the surgeon's role here a more formal footing. The review concludes that surgery in stage IV NSCLC should no longer be treated as an exception to standard practice but rather as an increasingly codified part of a biologically informed, multidisciplinary treatment strategy — while still acknowledging the real limitations of the current literature and the need for prospective, adequately powered trials.